Evidence map›Paper›PMID 29190822›Full record

ArticlePloS one2017

The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model.

Mahnaz Janghorban, Ellen M Langer, Xiaoyan Wang, Derek Zachman, Colin J Daniel, Jody Hooper, William H Fleming, Anupriya Agarwal, Rosalie C Sears

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Targeting PP2A in cancer: an underrated option.Journal of experimental & clinical cancer research : CR · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. mSphere · 2020
    Article
  9. Article
  10. Frontiers in cell and developmental biology · 2020
    Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mahnaz JanghorbanDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Ellen M LangerDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Xiaoyan WangDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Derek ZachmanPapé Family Pediatric Research Institute, Oregon Stem Cell Center, Department of Pediatrics, Portland, Oregon, United States of America.
Colin J DanielDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.
Jody HooperDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
William H FlemingPapé Family Pediatric Research Institute, Oregon Stem Cell Center, Department of Pediatrics, Portland, Oregon, United States of America.
Anupriya AgarwalKnight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States of America.
Rosalie C SearsDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, United States of America.ORCID http://orcid.org/0000-0003-1558-2413
Oregon Health & Science University · USJohns Hopkins University · US

Funding

Hydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2M
Cellular Mechanisms Controlling Myc Protein StabilityR01CA100855 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2003 to 2014
$3.6M
The Role of post-translational activation of Myc in pancreatic cancerR01CA196228 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2015 to 2019
$2.0M
c-Myc Phosphorylation Sites Regulate Its Apoptotic and Tumorigenic PotentialR01CA129040 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SEARS, ROSALIE C · 2008 to 2012
$1.6M
NCI NIH HHS R01 CA100855NCI NIH HHS R01 CA129040NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA196228
6 · The paper itself

Abstract

Protein phosphatase 2A (PP2A) is a ubiquitously expressed Serine-Threonine phosphatase mediating 30-50% of protein phosphatase activity. PP2A functions as a heterotrimeric complex, with the B subunits directing target specificity to regulate the activity of many key pathways that control cellular phenotypes. PP2A-B56α has been shown to play a tumor suppressor role and to negatively control c-MYC stability and activity. Loss of B56α promotes cellular transformation, likely at least in part through its regulation of c-MYC. Here we report generation of a B56α hypomorph mouse with very low B56α expression that we used to study the physiologic activity of the PP2A-B56α phosphatase. The predominant phenotype we observed in mice with B56α deficiency in the whole body was spontaneous skin lesion formation with hyperproliferation of the epidermis, hair follicles and sebaceous glands. Increased levels of c-MYC phosphorylation on Serine62 and c-MYC activity were observed in the skin lesions of the B56αhm/hm mice. B56α deficiency was found to increase the number of skin stem cells, and consistent with this, papilloma initiation was accelerated in a carcinogenesis model. Further analysis of additional tissues revealed increased inflammation in spleen, liver, lung, and intestinal lymph nodes as well as in the skin lesions, resembling elevated extramedullary hematopoiesis phenotypes in the B56αhm/hm mice. We also observed an increase in the clonogenicity of bone marrow stem cells in B56αhm/hm mice. Overall, this model suggests that B56α is important for stem cells to maintain homeostasis and that B56α loss leading to increased activity of important oncogenes, including c-MYC, can result in aberrant cell growth and increased stem cells that can contribute to the initiation of malignancy.

Indexed as

AnimalsMiceMice, TransgenicNeoplasms, ExperimentalNeoplastic Stem CellsProtein Phosphatase 2Protein Phosphatase 2

Identifiers

PMID29190822
PMCPMC5708644
OpenAlexW2772300025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.